A Delaware federal judge on Wednesday wiped out a $235 million verdict against Teva Pharmaceuticals for supposedly infringing a GlaxoSmithKline plc patent for the hypertension drug Coreg.

U.S. District Chief Judge Leonard P. Stark of the District of Delaware ruled in a post-trial opinion that the evidence in the case did not support a jury’s finding in June that Teva’s ”skinny label” for a generic version of the drug had caused doctors to infringe GSK’s patent.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]